CRISPR Therapeutics presented updated early data on its lipid-lowering gene editing therapy at the European Society of Cardiology meeting, showing mixed durability about a year after dosing. The company said it will pursue the highest dose in its program based on the updated profile. The update frames an important development choice for the gene-editing field: balancing target engagement and durability with dose optimization to improve long-term lipid control. It also indicates that the clinical readout was sufficient for CRISPR to adjust the dosing strategy rather than pause development. For stakeholders watching gene editing durability, the move signals ongoing iteration in trial design and dose selection as companies seek to extend pharmacodynamic effects over time.